Pig roundworms are parasitic worms of the genus Ascaris, within the family Ascarididae. These worms occur commonly in the intestines of pigs. They are mainly found in tropical and subtropical regions but can also be found in temperate climates. Pigs acquire the parasites through eating contaminated food or drinking contaminated water. Infection can cause intestinal obstruction, malabsorption, and stunted growth. Treatment and prevention include good hygiene practices, deworming, and avoiding eating undercooked pork or other infected animals.

Pig roundworm antigen is a type of protein found in the eggs of the Ascaris suum, a type of roundworm that infects pigs. This antigen is used in diagnostic tests to detect the presence of this parasite in pigs. It can also be used to induce an immune response in pigs, which can help them develop protection against this parasite.
Subheading: What is Pig Roundworm?

Recent studies have shown that pig roundworm can have a significant impact on the immune system of both pigs and humans. It has been found to increase the production of a protein called immunosuppressive ovarian message protein (IMP).

IMP is a hormone that is normally produced in the ovaries and helps regulate the female reproductive system. However, when levels of IMP become too high, it can suppress the immune system and make it more difficult for the body to fight off infections and diseases.

Pig roundworm cDNA and recombinant antigens have a wide range of applications in various fields of research. They can be used to study the genetic diversity of roundworms, to develop vaccines and treatments for roundworm infections, and to study the structure and function of roundworm proteins. In addition, they can be used to develop diagnostic tests for the detection of roundworm infections and to identify new genes and proteins involved in roundworm biology. They are also used to produce recombinant proteins for use in drug discovery and disease management.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.